About Globus Medical (NYSE:GMED)
Globus Medical, Inc. (Globus) is a medical device company focused on the design, development and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The Company is focused on implants that promote healing in patients with spine disorders. The Company's products fall into one of two categories: Innovative Fusion or Disruptive Technologies. The Company sells its products through exclusive sales force in the United States, as well as within North, Central & South America, Europe, Asia, Africa and Australia. The sales force consists of direct sales representatives and distributor sales representatives employed by exclusive independent distributors.
Industry, Sector and Symbol
Industry Medical Equipment, Supplies & Distribution
Sub-IndustryHealth Care Equipment
Trailing P/E Ratio39.545814052855
Forward P/E Ratio33.98
Sales & Book Value
Annual Sales$563.99 million
Price / Sales7.43
Cash Flow$1.68 per share
Price / Cash25.95
Book Value$8.67 per share
Price / Book5.02
Net Income$104.34 million
Return on Equity13.67%
Return on Assets12.35%
Globus Medical (NYSE:GMED) Frequently Asked Questions
What is Globus Medical's stock symbol?
Globus Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "GMED."
How were Globus Medical's earnings last quarter?
Globus Medical Inc (NYSE:GMED) released its quarterly earnings data on Wednesday, November, 8th. The medical device company reported $0.30 earnings per share for the quarter, meeting the consensus estimate of $0.30. The medical device company earned $151.74 million during the quarter, compared to analyst estimates of $150.73 million. Globus Medical had a net margin of 17.54% and a return on equity of 13.67%. Globus Medical's revenue for the quarter was up 11.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.29 EPS. View Globus Medical's Earnings History.
When will Globus Medical make its next earnings announcement?
What guidance has Globus Medical issued on next quarter's earnings?
Globus Medical updated its FY18 earnings guidance on Tuesday, January, 9th. The company provided earnings per share (EPS) guidance of $1.50 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.38. The company issued revenue guidance of approx $690 million, compared to the consensus revenue estimate of $679.92 million.
Where is Globus Medical's stock going? Where will Globus Medical's stock price be in 2018?
12 equities research analysts have issued 1-year target prices for Globus Medical's stock. Their forecasts range from $31.00 to $51.00. On average, they anticipate Globus Medical's stock price to reach $40.57 in the next twelve months. View Analyst Ratings for Globus Medical.
What are Wall Street analysts saying about Globus Medical stock?
Here are some recent quotes from research analysts about Globus Medical stock:
- 1. According to Zacks Investment Research, "Globus Medical, Inc. is a medical device company focused on the design, development and commercialization of products that promote healing in patients with spine disorders. The Company's products fall into one of two categories: innovative fusion or disruptive technologies. Its innovative fusion products address a broad range of spinal fusion surgical procedures. Its disruptive technology products include minimally invasive surgical, motion preservation and advanced biomaterials technologies. Globus Medical, Inc. is based in Audubon, Pennsylvania. " (1/10/2018)
- 2. Needham & Company LLC analysts commented, "GMED’s core spine organic growth has slowed though we expect some improvement in 2018 due to sales force enhancements. Its Emerging Technologies business should begin to add to growth in 2018 as well. But even accounting for this, we’re concerned that consensus 2018 estimates may be too high. And we believe that GMED’s earnings growth is going to be mostly driven by revenue growth." (9/26/2017)
- 3. Barclays PLC analysts commented, "ELGX’s 2Q17 sales of $48.6M (-4.7%) came in ahead of our/consensus estimates of $47.6M; higher OUS sales offset lighter US results impacted by sales force attrition and lower AFX2 sales recapture. Ovation growth remained strong. Net loss was better on higher sales, better GM, and lower opex. ELGX lowered FY17 guidance by $9M at the midpoint to $185-190M on lower AFX2 sales recapture and sales force attrition. ELGX expects to begin PMA enrollment for Gen2 Nellix in late 2017/early 2018. We expect a slight uptick in 2H17 sales as AFX2 US softness continues, offset by Ovation US growth. We assume higher growth in ’18 versus ’17 on easier ’17 comps from both AFX manufacturing issues and the narrowed Nellix IFU." (8/3/2017)
Who are some of Globus Medical's key competitors?
Some companies that are related to Globus Medical include Steris (STE), Bio-Rad Laboratories (BIO), West Pharmaceutical Services (WST), Hill-Rom (HRC), DexCom (DXCM), ICU Medical (ICUI), VWR (VWR), LivaNova (LIVN), Integra Lifesciences (IART), Haemonetics (HAE), Neogen (NEOG), NuVasive (NUVA), Inogen (INGN), Nevro (NVRO), Halyard Health (HYH), CONMED (CNMD), MiMedx Group (MDXG) and OraSure Technologies (OSUR).
Who are Globus Medical's key executives?
Globus Medical's management team includes the folowing people:
- David C. Paul, Executive Chairman of the Board (Age 50)
- Anthony L. Williams, President (Age 46)
- David M. Demski, Chief Executive Officer, Director (Age 59)
- Daniel T. Scavilla, Chief Financial Officer, Senior Vice President (Age 52)
- Andrew Brett Murphy, Group President, Commercial Operations (Age 52)
- Kurt C. Wheeler, Lead Independent Director (Age 64)
- David D. Davidar, Director (Age 51)
- Daniel T. Lemaitre, Independent Director (Age 63)
- Robert W. Liptak CPA, Independent Director (Age 53)
- Ann D. Rhoads, Independent Director (Age 51)
Who owns Globus Medical stock?
Globus Medical's stock is owned by a variety of of institutional and retail investors. Top institutional investors include GW&K Investment Management LLC (1.34%), Marathon Asset Management LLP (0.80%), Schwab Charles Investment Management Inc. (0.41%), RK Asset Management LLC (0.11%), Thomson Horstmann & Bryant Inc. (0.01%) and Bank of Montreal Can (0.01%). Company insiders that own Globus Medical stock include A Brett Murphy, Anthony L Williams, David D Davidar and Steven Payne. View Institutional Ownership Trends for Globus Medical.
Who sold Globus Medical stock? Who is selling Globus Medical stock?
Globus Medical's stock was sold by a variety of institutional investors in the last quarter, including GW&K Investment Management LLC, Bank of Montreal Can and First Citizens Bank & Trust Co.. Company insiders that have sold Globus Medical company stock in the last year include A Brett Murphy, Anthony L Williams, David D Davidar and Steven Payne. View Insider Buying and Selling for Globus Medical.
Who bought Globus Medical stock? Who is buying Globus Medical stock?
Globus Medical's stock was acquired by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc., Marathon Asset Management LLP, Thomson Horstmann & Bryant Inc. and RK Asset Management LLC. View Insider Buying and Selling for Globus Medical.
How do I buy Globus Medical stock?
Shares of Globus Medical can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Globus Medical's stock price today?
One share of Globus Medical stock can currently be purchased for approximately $43.50.
How big of a company is Globus Medical?
Globus Medical has a market capitalization of $4.19 billion and generates $563.99 million in revenue each year. The medical device company earns $104.34 million in net income (profit) each year or $1.10 on an earnings per share basis. Globus Medical employs 1,400 workers across the globe.
How can I contact Globus Medical?
Globus Medical's mailing address is 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403. The medical device company can be reached via phone at 610-930-1800 or via email at [email protected]
MarketBeat Community Rating for Globus Medical (GMED)MarketBeat's community ratings are surveys of what our community members think about Globus Medical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Globus Medical (NYSE:GMED) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Hold||Hold|
|Consensus Rating Score: ||2.58||2.50||2.38||2.20|
|Ratings Breakdown: ||1 Sell Rating(s)|
3 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
4 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
6 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
6 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$40.57||$36.83||$30.57||$28.00|
|Price Target Upside: ||9.56% downside||2.09% downside||1.33% upside||12.42% downside|
Globus Medical (NYSE:GMED) Consensus Price Target History
Globus Medical (NYSE:GMED) Analyst Ratings History
(Data available from 1/21/2016 forward)
Globus Medical (NYSE:GMED) Earnings History and Estimates Chart
Globus Medical (NYSE GMED) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/8/2017||Q3 2017||$0.30||$0.30||$150.73 million||$151.74 million||View||N/A|
|8/2/2017||Q2 2017||$0.30||$0.32||$150.94 million||$152.39 million||View||Listen|
|5/3/2017||Q1 2017||$0.31||$0.32||$155.81 million||View||Listen|
|2/27/2017||Q416||$0.33||$0.31||$149.30 million||$151.59 million||View||Listen|
|11/8/2016||Q3||$0.28||$0.29||$139.25 million||$135.70 million||View||Listen|
|7/26/2016||Q2||$0.29||$0.29||$141.78 million||$137.49 million||View||Listen|
|5/3/2016||Q1||$0.28||$0.29||$140.30 million||$139.30 million||View||Listen|
|2/24/2016||Q4||$0.30||$0.32||$141.20 million||$142.60 million||View||Listen|
|11/3/2015||Q3||$0.25||$0.28||$127.46 million||$137.00 million||View||Listen|
|7/30/2015||Q215||$0.25||$0.25||$126.89 million||$133.60 million||View||Listen|
|5/5/2015||Q115||$0.24||$0.26||$122.30 million||$131.60 million||View||Listen|
|2/25/2015||Q414||$0.25||$0.30||$127.77 million||$128.80 million||View||Listen|
|10/30/2014||Q314||$0.21||$0.24||$113.10 million||$117.80 million||View||Listen|
|8/5/2014||Q214||$0.23||$0.23||$119.83 million||$113.60 million||View||Listen|
|4/29/2014||Q114||$0.22||$0.24||$113.59 million||$114.20 million||View||Listen|
|2/26/2014||Q413||$0.22||$0.25||$114.96 million||$115.20 million||View||Listen|
|10/30/2013||Q313||$0.19||$0.22||$106.00 million||$107.19 million||View||Listen|
|8/1/2013||Q2 2013||$0.20||$0.21||$107.46 million||$107.00 million||View||Listen|
|5/2/2013||Q1 2013||$0.20||$0.21||$103.14 million||$105.00 million||View||Listen|
|2/27/2013||Q4 2012||$0.19||$0.22||$99.13 million||$100.50 million||View||Listen|
|11/1/2012||Q312||$0.19||$0.18||$95.32 million||$94.76 million||View||N/A|
Globus Medical (NYSE:GMED) Earnings Estimates
2018 EPS Consensus Estimate: $1.50
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Globus Medical (NYSE:GMED)
No dividend announcements for this company have been tracked by MarketBeat.com
Globus Medical (NYSE GMED) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 28.21%
Institutional Ownership Percentage: 70.24%
Globus Medical (NYSE GMED) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|12/15/2017||Steven Payne||CAO||Sell||3,076||$39.30||$120,886.80||23,847|| |
|12/13/2017||Anthony L Williams||President||Sell||15,000||$38.30||$574,500.00||15,000|| |
|12/4/2017||David D Davidar||Director||Sell||55,383||$40.66||$2,251,872.78||752,236|| |
|11/9/2017||A Brett Murphy||Insider||Sell||51,449||$35.00||$1,800,715.00||49,768|| |
|9/6/2017||A Brett Murphy||Insider||Sell||15,000||$29.99||$449,850.00||101,217|| |
|6/5/2017||Anthony L Williams||President||Sell||16,153||$31.94||$515,926.82||16,153|| |
|8/5/2016||A Brett Murphy||Insider||Sell||107,692||$23.37||$2,516,762.04||190,917|| |
|1/6/2016||Robert Liptak||Director||Sell||15,300||$27.50||$420,750.00||26,159|| |
|1/4/2016||Kurt Wheeler||Director||Sell||255||$27.50||$7,012.50||44,319|| |
|5/28/2015||Steven Payne||CAO||Sell||3,076||$25.92||$79,729.92|| |
|3/19/2015||David C Paul||CEO||Sell||1,922,000||$25.00||$48,050,000.00|| |
|1/15/2014||David Demski||COO||Sell||96,813||$20.51||$1,985,634.63||381,365|| |
|12/31/2013||David Demski||COO||Sell||3,187||$20.25||$64,536.75||478,178|| |
|12/20/2013||David Demski||COO||Sell||50,000||$19.75||$987,500.00||481,365|| |
|12/6/2013||Robert Liptak||Director||Sell||25,000||$19.36||$484,000.00||26,159|| |
|12/3/2013||David Davidar||VP||Sell||75,000||$19.25||$1,443,750.00||897,275|| |
|11/27/2013||David Demski||COO||Sell||37,323||$19.25||$718,467.75||531,365|| |
|11/1/2013||David M Demski||COO||Sell||112,677||$18.59||$2,094,665.43|| |
|8/23/2013||David Davidar||VP||Sell||7,278||$18.20||$132,459.60||997,499|| |
|8/22/2013||David Demski||COO||Sell||44,154||$17.95||$792,564.30||681,365|| |
|7/5/2013||David D Davidar||VP||Sell||10,000||$17.15||$171,500.00|| |
|7/1/2013||David D Davidar||VP||Sell||20,000||$16.56||$331,200.00|| |
|6/26/2013||David D Davidar||VP||Sell||150,000||$16.71||$2,506,500.00|| |
|8/8/2012||David C Paul||CEO||Sell||3,039,385||$11.16||$33,919,536.60|| |
|8/8/2012||David D Davidar||VP||Sell||166,885||$11.16||$1,862,436.60|| |
|8/8/2012||David M Demski||COO||Sell||98,957||$11.16||$1,104,360.12|| |
|8/8/2012||Kurt Wheeler||Director||Sell||804,232||$11.16||$8,975,229.12|| |
|8/8/2012||Steven Payne||CAO||Sell||2,305||$11.16||$25,723.80|| |
Globus Medical (NYSE GMED) News Headlines
|Globus Medical Inc (GMED) Receives Average Recommendation of "Buy" from Brokerages|
www.americanbankingnews.com - January 19 at 3:58 AM
|$0.34 EPS Expected for Globus Medical Inc (GMED) This Quarter|
www.americanbankingnews.com - January 17 at 3:10 AM
|Equities Analysts Issue Forecasts for Globus Medical Inc's FY2017 Earnings (GMED)|
www.americanbankingnews.com - January 15 at 2:38 AM
|Q4 2018 Earnings Forecast for Globus Medical Inc (GMED) Issued By William Blair|
www.americanbankingnews.com - January 12 at 8:02 PM
|FY2017 EPS Estimates for Globus Medical Inc (GMED) Lifted by William Blair|
www.americanbankingnews.com - January 11 at 8:04 AM
|Globus Medical (GMED) Upgraded to Hold at Zacks Investment Research|
www.americanbankingnews.com - January 11 at 12:10 AM
|Globus Medical (GMED) Receives "Sell" Rating from Barclays|
www.americanbankingnews.com - January 10 at 12:50 PM
|Globus Medical's (GMED) Outperform Rating Reiterated at Wells Fargo & Co|
www.americanbankingnews.com - January 10 at 8:20 AM
|Globus Medical (GMED) Updates FY18 Earnings Guidance|
www.americanbankingnews.com - January 9 at 9:12 AM
|Globus Medical (GMED) Stock Rating Lowered by Zacks Investment Research|
www.americanbankingnews.com - January 4 at 11:52 PM
|Medical Equipment Stocks' Research Reports Released on Medtronic, Edwards Lifesciences, Globus Medical, and ... - PR Newswire (press release)|
www.prnewswire.com - January 4 at 9:21 AM
|Morgan Stanley Upgrades Globus Medical, Expects 17% Upside - Benzinga|
www.benzinga.com - January 4 at 9:21 AM
|Globus Medical (GMED) Given a $45.00 Price Target at BTIG Research|
www.americanbankingnews.com - January 2 at 8:04 AM
|Head-To-Head Contrast: Halyard Health (HYH) & Globus Medical (GMED)|
www.americanbankingnews.com - December 31 at 11:14 PM
|$0.34 Earnings Per Share Expected for Globus Medical Inc (GMED) This Quarter|
www.americanbankingnews.com - December 31 at 11:26 AM
|Why Globus Medical Should Be on Your Watch List|
www.fool.com - December 30 at 1:07 AM
|ETFs with exposure to Globus Medical, Inc. : December 27, 2017|
finance.yahoo.com - December 27 at 1:49 PM
|Globus Medical, Inc. :GMED-US: Earnings Analysis: Q3, 2017 By the Numbers : December 26, 2017|
finance.yahoo.com - December 26 at 2:33 PM
|Financial Comparison: Antares Pharma (ATRS) vs. Globus Medical (GMED)|
www.americanbankingnews.com - December 25 at 11:06 AM
|Globus Medical Inc (GMED) Receives Average Rating of "Hold" from Analysts|
www.americanbankingnews.com - December 25 at 3:57 AM
|First Week of GMED February 2018 Options Trading|
www.nasdaq.com - December 20 at 9:23 AM
|Insider Selling: Globus Medical Inc (GMED) CAO Sells 3,076 Shares of Stock|
www.americanbankingnews.com - December 18 at 6:20 PM
|$165.40 Million in Sales Expected for Globus Medical Inc (GMED) This Quarter|
www.americanbankingnews.com - December 16 at 9:56 AM
|Globus Medical Inc (GMED) President Sells $574,500.00 in Stock|
www.americanbankingnews.com - December 14 at 5:34 PM
|Globus Medical Inc (GMED) Expected to Announce Earnings of $0.34 Per Share|
www.americanbankingnews.com - December 14 at 9:50 AM
|Globus Medical Inc Forecasted to Earn FY2020 Earnings of $1.65 Per Share (GMED)|
www.americanbankingnews.com - December 14 at 12:50 AM
|Globus Medical Inc (GMED) Forecasted to Post FY2019 Earnings of $1.50 Per Share|
www.americanbankingnews.com - December 13 at 11:28 PM
|Head-To-Head Contrast: Baxter International (BAX) vs. Globus Medical (GMED)|
www.americanbankingnews.com - December 10 at 5:22 AM
|Head-To-Head Contrast: Globus Medical (GMED) and Its Peers|
www.americanbankingnews.com - December 9 at 5:30 AM
|Analyzing Globus Medical (GMED) & Its Rivals|
www.americanbankingnews.com - December 7 at 11:34 PM
|Globus Medical (GMED) and Its Peers Critical Review|
www.americanbankingnews.com - December 7 at 3:38 PM
|Insider Selling: Globus Medical, Inc. (GMED) Director Sells 55,383 Shares of Stock|
www.americanbankingnews.com - December 6 at 5:22 PM
|Globus Medical (GMED) and Its Rivals Head to Head Analysis|
www.americanbankingnews.com - December 5 at 3:30 PM
|Bloomberg Markets: CVS Buying Aetna, Facebook’s New Kids App|
www.bloomberg.com - December 5 at 10:02 AM
|Wells Fargo & Company Upgrades Globus Medical (GMED) to "Outperform"|
www.americanbankingnews.com - December 4 at 8:58 PM
|Globus Medical (GMED) Downgraded by ValuEngine|
www.americanbankingnews.com - December 3 at 12:06 PM
|Globus Medical Announces Clinical Results Showing Superiority of its SECURE-C® to ACDF at Seven Years - GlobeNewswire (press release)|
globenewswire.com - December 1 at 4:44 PM
|Report: Developing Opportunities within Procter & Gamble, ACADIA Pharmaceuticals, Cree, Umpqua, Westrock, and Globus Medical — Future Expectations, Projections Moving into 2018|
finance.yahoo.com - November 30 at 9:32 AM
|Globus Medical, Inc. (GMED) Given Consensus Rating of "Buy" by Analysts|
www.americanbankingnews.com - November 30 at 3:38 AM
|$165.40 Million in Sales Expected for Globus Medical, Inc. (GMED) This Quarter|
www.americanbankingnews.com - November 28 at 9:50 AM
|Technical Perspectives on Edwards Lifesciences, Globus Medical, Invacare, and Medtronic - PR Newswire (press release)|
www.prnewswire.com - November 28 at 9:14 AM
|$0.34 EPS Expected for Globus Medical, Inc. (GMED) This Quarter|
www.americanbankingnews.com - November 26 at 9:12 AM
|Globus Medical, Inc. (GMED) Upgraded to "Buy" by BidaskClub|
www.americanbankingnews.com - November 26 at 6:10 AM
|Globus Medical (GMED) versus NuVasive (NUVA) Financial Survey|
www.americanbankingnews.com - November 24 at 5:12 PM
|Mazor Robotics Might Need to Worry About This Potential Rival the Most (Hint: It's Not Intuitive Surgical)|
finance.yahoo.com - November 22 at 7:57 PM
|Palomar Medical Technologies (PMTI) & Globus Medical (GMED) Head-To-Head Review|
www.americanbankingnews.com - November 21 at 5:12 AM
|Globus Medical, Inc. (GMED) Earns Buy Rating from BTIG Research|
www.americanbankingnews.com - November 20 at 8:58 AM
|Globus Medical, Inc. (GMED) Receives "Buy" Rating from Gabelli|
www.americanbankingnews.com - November 14 at 4:00 PM
|Stocks Showing Market Leadership: Globus Medical Earns 91 RS Rating|
finance.yahoo.com - November 13 at 6:01 PM
|Equities Analysts Set Expectations for Globus Medical, Inc.'s FY2019 Earnings (GMED)|
www.americanbankingnews.com - November 13 at 5:34 PM
Globus Medical (NYSE:GMED) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Globus Medical (NYSE:GMED) Income Statement, Balance Sheet and Cash Flow Statement
Globus Medical (NYSE GMED) Stock Chart for Sunday, January, 21, 2018